Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced the international publication of its PCT application WO 2026/062177 A1, covering SIRT6 variants for prevention and treatment of muscular diseases including frailty syndrome and sarcopenia.
The publication broadens Genflow's SIRT6 IP scope internationally, preserves multi-jurisdictional patent filing options, and supports potential development and partnering of its gene therapy platform.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as of 31 March 2026. The company has 535,653,205 ordinary shares of £0.0003 each, with none held in treasury, so total voting rights equal 535,653,205.
Shareholders may use this figure as the denominator for FCA Disclosure Guidance and Transparency Rules notifications regarding changes in shareholding.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) raised £800,000 by issuing 42,105,263 new ordinary shares at 1.9p each, with one warrant per subscription share exercisable at the same price for two years. Admission of the new shares is expected around 11 March 2026.
The net proceeds are intended to fund scientific programs, extend cash runway and support potential licensing negotiations; CEO Eric Leire and chairman Gad Berdugo participated in the Subscription.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that all resolutions at its General Meeting on March 2, 2026 were duly passed by shareholders. Proxy voting showed strong support for both the directors' authority to allot securities and the disapplication of pre-emption rights.
The company reported vote totals and percentages for each resolution, with over 97% of votes cast in favour on both items and detailed proxy counts provided.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) confirmed receipt of the first instalment of a €4.0 million non-dilutive grant from the Wallonia Region.
The company received €336,467 on March 2, 2026, for a three-year development programme supporting GF-1002 in MASH, with further instalments tied to milestone-based disbursements and applied to eligible project activities.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) reports positive preliminary interim results from the SLAB trial testing its SIRT6 gene therapy in aged beagles. The randomised, blinded study enrolled 24 dogs aged >10 years across four groups. During the dosing period, all treated cohorts showed superior survival, functional gains and a favourable safety profile versus control. Key mechanistic endpoints—methylation clock and muscle histology—remain under analysis, with a comprehensive update expected within approximately two months.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) has called a General Meeting for 11:00 on 2 March 2026 to seek shareholder authority to issue up to 188,947,368 new ordinary shares (~38% of current issued share capital) to enable a potential equity raise.
The raise would be by private placement, may include warrants, and proceeds are intended for IND-enabling work on MASH, an aged-beagle trial payment, glaucoma PoC studies, business development, and patent work.
Genflow Biosciences (OTC:GENFF) major-holdings notice: Jonathan Mark Swann crossed a regulatory threshold, increasing his direct voting stake to 12.13% of voting rights (59,861,278 votes) on 23-Jan-2026. The issuer notified the market on 25-Jan-2026 and the completion date is listed as 24-Jan-2026.
The filing shows a prior position of 11.32% (55,861,278 votes), no voting rights via financial instruments, and no additional information disclosed.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received administrative approval for approximately €4 million in non-dilutive funding from the Wallonia Region to support GF-1002 development for MASH.
First instalment expected no later than May 2026; support covers a three-year programme and makes 2026 priorities capital-efficient, with multiple programme readouts planned.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) appointed Gad Berdugo as Independent Non-Executive Chairman effective immediately, while Tamara Joseph remains on the board to preserve continuity and governance. Mr. Berdugo brings over 30 years of leadership across biotech corporate development, U.S. capital markets and RNA-LNP therapeutics, and currently leads Explorium Capital LLC. The company said his expertise will support advancement of gene-therapy programs, evaluation of delivery technologies, and expanded U.S. engagement. Management highlighted key data readouts expected in 2026. The announcement notes Mr. Berdugo does not own any Genflow shares.